Summary by Moomoo AI
GSK announced positive results from the DREAMM-7 phase III trial for Blenrep (belantamab mafodotin) in relapsed/refractory multiple myeloma. The trial met its key secondary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of death when Blenrep was combined with bortezomib and dexamethasone (BorDex) compared to daratumumab plus BorDex.Full data will be presented at the American Society of Hematology Annual Meeting on December 9, 2024. GSK plans to share these results with health authorities to support regulatory filings. Blenrep combinations have already been filed for approval in several countries based on DREAMM-7 and DREAMM-8 trial results.The DREAMM-7 trial involved 494 patients with relapsed/refractory multiple myeloma who had received at least one prior line of therapy. The positive overall survival results highlight Blenrep's potential to extend patients' lives and potentially transform treatment in this setting. GSK continues to evaluate Blenrep in earlier treatment lines and in combination with other therapies through its DREAMM clinical development program.
